8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Jan 21, 2026·SEC
TherapeuticsMD, Inc.(TXMD)Earnings, Financials & Key Ratios
TXMD•NASDAQ
$1.97
Price updated Jul 6, 2026
AboutTherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Show more
- Revenue$3M+71.6%
- EBITDA-$3M+28.9%
- Net Income-$569K+73.9%
- EPS (Diluted)-0.05+74.1%
- Gross Margin100%
- EBITDA Margin-99.97%+58.6%
- Operating Margin-139.44%+48.4%
- Net Margin-18.83%+84.8%
- ROE-2.1%+72.8%
TXMD Price & Volume
TherapeuticsMD, Inc. (TXMD) stock price & volume — 10-year historical chart
Loading chart...
Royalty Transition Masks Persistent Corporate Administrative Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Administrative overhead exceeding revenue
Key Thesis Takeaways
- TherapeuticsMD has pivoted to a royalty-dependent business model, resulting in structural gross margins of 100% in most recent quarters, yet the firm remains hampered by fixed administrative expenses that frequently exceed its volatile quarterly revenue.
- While the company has successfully reduced its total debt from $8.0 million in 2023Q4 to $4.8 million in 2026Q1, the persistent operating losses and a massive accumulated deficit of $952.3 million raise significant concerns regarding long-term corporate viability.
- Investors should monitor the company's ability to sustain its $8.4 million cash position against ongoing operational burn, as the current trajectory suggests limited flexibility for future strategic pivots.
Verdict Logic
the company's reliance on erratic royalty inflows to cover fixed costs, combined with a massive $952.3 million accumulated deficit, suggests that the current corporate shell lacks the scale to achieve sustainable profitability.
TXMD Growth Metrics
TherapeuticsMD, Inc. (TXMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-17.28%
5 Years-45.84%
3 Years-64.91%
TTM82.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM108.52%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM108.47%
Return on Capital
10 Years-86.65%
5 Years-90.68%
3 Years-15.84%
Last Year-12.67%
TXMD Recent Earnings
TherapeuticsMD, Inc. (TXMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (44%)●Beat Revenue 1/12 qtrs (11%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.01+100.2%
$6.13
Rev
$724,000-96.3%
$20M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.05+99.1%
$6.13
Rev
$893,000-95.5%
$20M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.01
—
Rev
$784,000
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.05
—
Rev
$952,000
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.01vs $6.13+100.2% | $724,000vs $20M-96.3% |
| Q2 2026 | Mar 30, 2026 | $0.05vs $6.13+99.1% | $893,000vs $20M-95.5% |
| Q4 2025 | Nov 12, 2025 | $0.01 | $784,000 |
| Q3 2025 | Aug 12, 2025 | $0.05 | $952,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for TherapeuticsMD, Inc. (TXMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.97 | $22.8M | -40.04 | 71.61% | -18.83% | -2.1% | — | |
| $30.93 | $2.42B | 47.58 | 10.4% | 5.23% | 13.34% | — | |
| $2.08 | $30.21M | -1.73 | 10429.36% | -1038.77% | — | — | |
| $85.05 | $1.93B | 25.62 | 43.78% | 9.71% | 17.32% | — | |
| $3.38 | $21.35M | -2.79 | 125.12% | -102.42% | -61.46% | — | |
| $254.76 | $450.11B | 107.49 | 8.57% | 5.79% | 67.46% | — |
Compare TXMD vs Peers
TherapeuticsMD, Inc. (TXMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TXMD SEC Filings & Documents
TherapeuticsMD, Inc. (TXMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TXMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TXMD Frequently Asked Questions
TherapeuticsMD, Inc. (TXMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is TherapeuticsMD, Inc.'s revenue?
TherapeuticsMD, Inc. (TXMD) reported $3.4M in revenue for fiscal year 2025. This represents a 1274% increase from $0.2M in 1996.
How fast is TherapeuticsMD, Inc. growing?
TherapeuticsMD, Inc. (TXMD) grew revenue by 71.6% over the past year. This is strong growth.
Is TXMD profitable?
Yes, TherapeuticsMD, Inc. (TXMD) is profitable, generating $0.2M in net income for fiscal year 2025 (-18.8% net margin).
Dividend & Returns
What is TXMD's return on equity?
TherapeuticsMD, Inc. (TXMD) has a return on equity (ROE) of -2.1%. Negative ROE indicates the company is unprofitable.
What is TherapeuticsMD, Inc.'s free cash flow?
TherapeuticsMD, Inc. (TXMD) generated $2.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.